Cathie Wood’s ARK Files 13G/A for 1.7M Arcturus Shares
Rhea-AI Filing Summary
Schedule 13G/A (Amendment 8) filed on 07/30/2025 discloses that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood collectively hold a significant position in Arcturus Therapeutics Holdings Inc. (ARCT).
- Shares beneficially owned: 1,715,040 common shares.
- Ownership percentage: 6.32 % of ARCT’s outstanding stock.
- Voting & dispositive power: ARK has sole voting and dispositive power over the full position; Wood has shared power through her control of ARK.
- Form type of filer: ARK is an investment adviser (IA); Wood is reported as a holding-company/control person (HC, IN).
- Client concentration: The ARK Genomic Revolution ETF is the only ARK client with an interest >5 % of ARCT.
The filing states the shares were acquired and are held in the ordinary course of business and not with the intent to influence control of the issuer.
Positive
- ARK Investment Management and Catherine D. Wood disclose a 6.32 % stake (1.715 M shares) in ARCT, underscoring continued institutional ownership.
Negative
- None.
Insights
TL;DR: ARK still owns 6.3 % of ARCT; disclosure is routine, confirming continued institutional backing without signaling strategy change.
The amendment shows ARK and Cathie Wood retain 1.72 M shares, equal to 6.32 % of the float—above the 5 % threshold that triggers a Schedule 13G filing. All voting and dispositive power resides with ARK, aligning with its role as investment adviser; Wood’s shared power reflects her control position. No new purchase or sale data is provided, so the filing is largely administrative. For investors, the key takeaway is that a high-profile growth-oriented manager remains a >5 % holder, which may be viewed as supportive of market perception but does not, on its own, alter ARCT’s fundamentals or near-term outlook.